Drugs / CC-94676
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04428788 | Jun 2020 → Oct 2025 | prostate neoplasm | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-94676 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04428788 ↗ |